Colgate-Palmolive (NYSE:CL) PT Set at $75.00 by Barclays

Colgate-Palmolive (NYSE:CL) received a $75.00 target price from analysts at Barclays in a report released on Thursday, March 15th. The brokerage presently has a “hold” rating on the stock. Barclays’ price target suggests a potential upside of 4.69% from the company’s previous close.

CL has been the subject of a number of other research reports. BNP Paribas lowered Colgate-Palmolive from an “outperform” rating to an “underperform” rating in a research note on Tuesday, January 30th. Zacks Investment Research lowered Colgate-Palmolive from a “hold” rating to a “sell” rating in a research note on Tuesday, December 19th. Deutsche Bank assumed coverage on Colgate-Palmolive in a research note on Wednesday, December 13th. They set a “hold” rating and a $75.00 price objective for the company. Citigroup raised their price objective on Colgate-Palmolive from $75.00 to $80.00 and gave the company a “neutral” rating in a research note on Tuesday, January 30th. Finally, KeyCorp restated a “hold” rating on shares of Colgate-Palmolive in a research note on Saturday, November 25th. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $77.76.

How to Become a New Pot Stock Millionaire

Colgate-Palmolive stock traded down $0.17 during trading hours on Thursday, hitting $71.64. The stock had a trading volume of 2,922,554 shares, compared to its average volume of 3,688,603. The company has a debt-to-equity ratio of 27.02, a quick ratio of 1.00 and a current ratio of 1.36. The firm has a market capitalization of $62,708.43, a price-to-earnings ratio of 24.96, a price-to-earnings-growth ratio of 2.65 and a beta of 0.74. Colgate-Palmolive has a 1-year low of $67.86 and a 1-year high of $77.91.

Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings data on Friday, January 26th. The company reported $0.75 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.75. Colgate-Palmolive had a return on equity of 1,716.69% and a net margin of 13.10%. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the prior year, the business earned $0.75 earnings per share. The business’s revenue was up 4.6% on a year-over-year basis. sell-side analysts forecast that Colgate-Palmolive will post 3.18 EPS for the current fiscal year.

In other news, CFO Dennis J. Hickey sold 5,651 shares of Colgate-Palmolive stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $70.18, for a total transaction of $396,587.18. Following the transaction, the chief financial officer now directly owns 413,221 shares in the company, valued at approximately $28,999,849.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Daniel B. Marsili sold 5,692 shares of Colgate-Palmolive stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $70.19, for a total value of $399,521.48. Following the transaction, the insider now owns 41,677 shares in the company, valued at $2,925,308.63. The disclosure for this sale can be found here. In the last three months, insiders sold 455,707 shares of company stock worth $32,443,427. Company insiders own 1.02% of the company’s stock.

Several hedge funds have recently modified their holdings of CL. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Colgate-Palmolive by 15.7% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 81,249 shares of the company’s stock valued at $6,130,000 after buying an additional 11,036 shares in the last quarter. Certified Advisory Corp purchased a new position in shares of Colgate-Palmolive during the fourth quarter valued at $143,000. Ackerman Capital Advisors LLC purchased a new position in shares of Colgate-Palmolive during the fourth quarter valued at $368,000. Colonial Trust Advisors grew its holdings in shares of Colgate-Palmolive by 22.5% during the fourth quarter. Colonial Trust Advisors now owns 16,653 shares of the company’s stock valued at $1,256,000 after buying an additional 3,062 shares in the last quarter. Finally, Cedar Hill Associates LLC purchased a new position in shares of Colgate-Palmolive during the fourth quarter valued at $203,000. Institutional investors own 73.67% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/colgate-palmolive-cl-given-a-75-00-price-target-by-barclays-analysts.html.

About Colgate-Palmolive

Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.

Analyst Recommendations for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply